Ipsen ((GB:0MH6)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Study Overview: Ipsen is conducting a Phase III clinical trial titled A Phase III, Randomised, Double-blind, Placebo-controlled, Multicenter, Parallel-group Study With Extension Phase to Evaluate the Efficacy and Safety of Dysport® for the Prevention of Episodic Migraine in Adult Participants. The study aims to assess the safety and effectiveness of Dysport®, a formulation of Botulinum toxin type A, in preventing episodic migraines, which are characterized by severe headaches occurring less than 15 days a month.
Intervention/Treatment: The study tests Dysport®, a Botulinum toxin type A, administered intramuscularly to prevent the release of chemicals causing migraine pain. Participants receive either Dysport® or a placebo during the study.
Study Design: The trial is interventional with a randomized, parallel assignment. It is double-blind, meaning neither participants nor investigators know who receives Dysport® or placebo. The primary goal is prevention.
Study Timeline: The study began on September 14, 2023, with primary completion expected by August 26, 2025. These dates are crucial for tracking progress and anticipating results.
Market Implications: Ipsen’s stock performance may be influenced by this study’s outcomes, as positive results could enhance Dysport®’s market position in migraine prevention. Competitors in the migraine treatment market will be closely monitoring these developments.
The study is ongoing, and further details are available on the ClinicalTrials portal.